Company Overview of Selecta Biosciences, Inc.
Selecta Biosciences, Inc., a biopharmaceutical company, discovers and develops nanoparticle immunomodulatory drugs and vaccines for the treatment and prevention of human diseases. Its products are designed to deliver bioactive molecules to specific immune cells in the body. The company’s immunomodulatory nanoparticle platform technology enables interaction with the immune system to treat and prevent various diseases, as well as enables the rational design of targeted immunomodulatory nanoparticles that induce or modify cellular and/or humoral immune responses for therapeutic and prophylactic indications. Selecta Biosciences, Inc. has a strategic collaboration with Sanofi. The company was fou...
480 Arsenal Street
Watertown, MA 02472
Founded in 2007
Key Executives for Selecta Biosciences, Inc.
Co-Founder and Co-Chair of the Scientific Advisory Board
Vice President of Finance
Compensation as of Fiscal Year 2012.
Selecta Biosciences, Inc. Key Developments
Selecta Biosciences, Inc. and Sanofi Sign Global Collaboration to Develop Antigen-Specific Immunotherapies for up to Three Allergy Indications Based on Selecta's Synthetic Vaccine Particle Technology
Nov 28 12
Selecta Biosciences, Inc. announced that it has entered into a strategic global collaboration with Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies. Under the agreement, Sanofi obtains an exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies each to a specific food or aeroallergen. The products resulting from this collaboration will leverage Selecta's proprietary Synthetic Vaccine Particle (SVP(TM)) platform which has unique capabilities to engineer nanoparticles with the ideal structure and composition to produce immune tolerance by balancing the overactive response to specific allergy-causing antigens. Under the terms of the agreement Selecta is eligible to receive several pre-clinical, clinical, regulatory and sales milestones totaling $300 million per allergen indication for up to three immunotherapy candidates contemplated by this collaboration. Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for each commercialized immunotherapy. As part of the research alliance, Sanofi will work together with Selecta to design antigen-specific immunotherapies that meet unmet needs as defined by Sanofi for applications where Selecta's technology can offer a new therapeutic approach for life-threatening and other severe allergies. Under the terms of the agreement, Sanofi will have access to Selecta's proprietary Synthetic Vaccine Particle (SVP(TM)) platform that is designed to create robust antigen-specific immune responses for superior immunotherapy effectiveness. This collaboration is aligned with Sanofi's strategic focus areas in immunology and leverages Sanofi's Boston-based research and development capabilities.
Selecta Biosciences, Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 11:50 AM
Nov 26 12
Selecta Biosciences, Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 11:50 AM. Venue: Westin Copley Place, Boston, Massachusetts, United States.
Selecta Biosciences, Inc. Presents at EBD Group, Inc.'s Biotech Showcase 2012, Jan-10-2012 10:30 AM
Dec 14 11
Selecta Biosciences, Inc. Presents at EBD Group, Inc.'s Biotech Showcase 2012, Jan-10-2012 10:30 AM. Venue: Parc 55 Wyndham San Francisco Union Square, 55 Cyril Magnin Street, San Francisco, 94102, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|